Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 4/20 | 0.53 |
| ▸ | TOP1 | P11387 | 1/20 | 0.49 |
| ▸ | CYCS | P99999 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.44 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8909617 | 0.99 | FABP4 (0.52) | FABP4TOP1CYCSLMNADHFR | |
| SCHEMBL8908536 | 0.99 | FABP4 (0.52) | FABP4TOP1CYCSLMNADHFR | |
| SCHEMBL8909527 | 0.89 | TOP1 (0.45) | FABP4TOP1CYCS | |
| SCHEMBL8909582 | 0.88 | TOP1 (0.44) | FABP4TOP1CYCS | |
| SCHEMBL8908515 | 0.88 | TOP1 (0.44) | FABP4TOP1CYCS | |
| Hydrochloric Acid SCHEMBL8865595 | 0.87 | TOP1 (0.43) | FABP4TOP1CYCS | |
| Hydrochloric Acid SCHEMBL8865553 | 0.87 | TOP1 (0.43) | FABP4TOP1CYCS | |
| SCHEMBL10730297 | 0.86 | MEN1 (0.57) | TOP1CYCSMEN1KMT2APTPN7 | |
| SCHEMBL29558419 | 0.84 | TOP1 (0.61) | TOP1CYCSMEN1KMT2APDE2A | |
| SCHEMBL3794157 | 0.84 | TOP1 (0.61) | TOP1CYCSMEN1KMT2APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0684948-B1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | DIAGNOSTIKFORSCHUNG INST (DE) | 1997-10-22 | — | — | EP | claimed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | claimed |
| US-6436365-B2 | ADMINISTRATION VIA CATHETER OF RADIOACTIVE METAL COMPLEX TO SITE OF LEGION; TREATMENT OF ATHERSCLEROSIS; REDUCES UNDESIRED RADIOACTIVE EXPOSURE OF HEALTHY TISSUE | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-08-20 | — | — | US | disclosed |
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2002-01-10 | — | — | US | disclosed |
| EP-1011737-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1999013920-A2 | METHOD FOR TREATING PROLIFERATIVE DISEASES BY THERAPY | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-25 | — | — | WO | disclosed |
| EP-0684948-B1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | DIAGNOSTIKFORSCHUNG INST (DE) | 1997-10-22 | — | — | EP | disclosed |
| EP-0684948-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME. | DIAGNOSTIKFORSCHUNG INST (DE) | 1995-12-06 | — | — | EP | disclosed |
| WO-1994019352-A1 | MESO-TETRAPHENYL PORPHYRIN COMPLEX COMPOUNDS, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICALS CONTAINING THE SAME | Institut für Diagnostikforschung GmbH an der Freien Universität Berlin (DE) | 1994-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004031-A1 | PROCESS FOR THERAPEUTIC TREATMENT OF PROLIFERATIVE DISEASES | MKI67, FGF2, FGFR1 | FABP4 2040/4885TOP1 3543/4885CYCS 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.